Close Menu

NEW YORK – Guardant Health reported after the close of the market on Wednesday that its fourth quarter 2020 revenues rose 25 percent year over year, driven by an increase in clinical testing volumes and revenue.

The Redwood City, California-based cancer genomics and early detection firm said its total revenues for the three months ended Dec. 31, 2020 were $78.3 million compared to $62.9 million in the same quarter of 2019, beating the $76.7 million that Wall Street analysts, on average, had predicted.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.